https://sohoinsider.com/news/afm13-cd30-lymphoma-trial/
SOHO Insider - AFM13 Shows Promise in CD30 Lymphoma Trial
Apr 17, 2025 - AFM13 with NK cells yields 92.9% response in CD30 lymphoma refractory to brentuximab, per phase 1 trial in Nature Medicine.
sohoinsidershowspromiselymphoma